@article{b926af86e40744d3aa852e3103b49684,
title = "Psychedelics: Old drugs, new trips",
author = "Rucker, {James J.} and Pallab Seth",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: James Rucker is funded by a fellowship (CS-2017-17-007) from the National Institute for Health Research (NIHR). Funding Information: James Rucker leads the Psychedelic Trials Group at King{\textquoteright}s College London. King{\textquoteright}s College London receives grant funding from COMPASS Pathways PLC to undertake phase 1 and phase 2 trials with psilocybin. COMPASS Pathways PLC has paid for James Rucker to attend trial related meetings and conferences to present the results of research using psilocybin. James Rucker has undertaken paid consultancy work for Beckley PsyTech and Clerkenwell Health. Payments for consultancy work are received and managed by King{\textquoteright}s College London. James Rucker does not benefit personally. This work presents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = apr,
doi = "10.1177/02698811211003495",
language = "English",
volume = "35",
pages = "316--318",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd STM",
number = "4",
}